KPV peptide: what the research covers and where the FDA stands

KPV is a peptide of just three amino acids (lysine, proline and valine) cut from the end of the hormone alpha-MSH, and everything known about it comes from lab and animal studies. It isn’t FDA-approved, and as of October 27, 2026 a licensed pharmacy may not compound it, even though an FDA advisory committee voted for it in July. The FDA’s own reviewers found no study in which KPV was given to a person, by any route. This guide covers what KPV is, what its research actually measured, and what the FDA has and hasn’t decided. It doesn’t point to any seller, because there is no lawful source today.

What is KPV?

KPV is named for its three amino acids in one-letter code: K for lysine, P for proline and V for valine. It is the last three amino acids of alpha-melanocyte-stimulating hormone (alpha-MSH), a hormone the pituitary gland makes. The FDA’s review describes KPV as “reported to be a tripeptide” and notes that it is “naturally produced in the body” as a fragment of alpha-MSH (FDA briefing document).

As a drug ingredient, KPV is poorly defined. It has no United States Adopted Name, no USP or National Formulary monograph and no place in any FDA-approved drug. The FDA’s reviewers found products sold as KPV in more than one form, including a free base and an acetate salt, and said that “multiple salts, and derivatives, including different active moieties” are sold under the same common name. They called that a risk to patients, who “may be dosed with a different” substance than the one the prescriber ordered.

Online, KPV is sold as injections, oral products, creams and nasal sprays, and it is often mixed with other peptides. The FDA’s review lists claims from clinic and seller websites that it helps inflammatory bowel disease, psoriasis, wound healing, mast cell activation, mold toxicity and recovery from COVID-19. None of those uses has been tested in people.

KPV peptides benefits: what the studies measured

The evidence for KPV is preclinical: experiments on cells and animals, which show how a molecule behaves in a model but not whether it helps or harms people. Here is what the main studies looked at.

Gut inflammation in cells and mice. The study cited most often online, by researchers at Emory University, was published in Gastroenterology in 2008 (Dalmasso et al.). They exposed human intestinal cells and human immune cells, grown in a dish, to inflammatory signals with and without KPV, and measured inflammatory signaling and the cytokines the cells released. They also gave KPV in drinking water to mice with colitis induced by chemicals, and measured inflammation in the colon under the microscope and by cytokine gene activity. The study also examined how KPV gets into cells, through a transporter called PepT1.

Wounds in rodents. The FDA’s reviewers cite rodent studies of KPV and wound healing, and a 2019 paper in Experimental Dermatology whose authors wrote that clinical studies are still needed to learn whether KPV could help heal skin wounds and ulcers.

Skin absorption. In a lab test on skin from human donors after death, KPV did not pass through the skin well, according to the FDA’s summary of that study. The FDA noted that this could limit how much a cream delivers below the skin’s outer layer.

People. None. The pharmacy that nominated KPV cited nine references, and the FDA says “none were studies of KPV administered in humans”. The FDA’s own literature search, covering PubMed, Embase, ClinicalTrials.gov and other databases, found no human data either. It also found no adverse event reports for KPV in its FAERS drug database or in its complaint system for foods and supplements, and cautions that FAERS data alone can’t support conclusions about safety.

What the FDA has decided

Off Category 2, into no category

Under section 503A, a pharmacy may compound only with bulk ingredients that have a USP or National Formulary monograph, are part of an FDA-approved drug, or are on the FDA’s 503A bulks list (FDA). While it builds that list, the FDA doesn’t act against pharmacies using substances in its Category 1.

KPV was nominated as a topical cream or gel for wound healing and for inflammatory conditions such as psoriasis and eczema. The FDA placed it in Category 2, its list of substances that may raise significant safety risks. When the nomination was withdrawn, the FDA moved KPV to its list of substances “nominated but withdrawn”, where the safety note still reads that the FDA “has not identified any human exposure data on drug products containing KPV administered via any route of administration” (FDA). That move left KPV in no category, which doesn’t make it eligible for compounding.

The FDA’s review: weighs against

Although the nomination was withdrawn, the FDA evaluated KPV on its own initiative for its advisory committee. The review, dated May 12, 2026, concluded that “a balancing of the criteria weighs against” putting KPV on the bulks list. Its reasons: KPV is not well characterized chemically, how widely it is used in compounding is unknown, there is no information on its use in humans to judge safety or effectiveness, and approved treatments already exist for wounds, psoriasis and eczema.

What the FDA hasn’t decided

The July 23, 2026 vote

The FDA’s Pharmacy Compounding Advisory Committee took up KPV on the morning of July 23, 2026, voting separately on KPV free base and KPV acetate (FDA). According to a law-firm report of the meeting, the committee voted 8 to 6, with 1 abstention, to recommend KPV, against the FDA review team’s recommendation (McDermott). The FDA has not posted minutes or an official vote count.

Why the vote doesn’t change the rules yet

The FDA describes its advisory committees as making “non-binding recommendations” that it generally follows but is not legally bound to follow (FDA). To add KPV to the bulks list, the FDA would have to publish a proposed rule in the Federal Register, take public comments and issue a final rule. As of October 27, 2026, the Federal Register shows no such proposal, and the FDA’s categories list is still the version updated May 14, 2026.

If the FDA did add KPV, a 503A pharmacy could compound it for an individual patient’s prescription. It would still not be an FDA-approved drug, and no FDA review would have found it safe or effective for any use.

BPC-157 and KPV together

KPV is often sold alongside BPC-157, in blends such as KLOW and in what the FDA’s review calls a “regenerative combo” with BPC-157, TB-500, AOD-9604 and follistatin-344. The two have a lot in common on paper:

• The committee reviewed both on the morning of July 23, 2026, and both drew a reported 8 to 6 vote in favor.
• The FDA’s reviewers recommended against both. For BPC-157 they cited poor chemical characterization, limited safety data and immune-reaction risk for injected and nasal forms (FDA).
• Neither can be compounded today, so a blend containing either can’t be lawfully compounded either.
• No study has tested the two together in people.

Our guides to BPC-157 and to the GLOW and KLOW blends cover the rest of those mixes.

KPV sold for research

Most KPV sold online comes as a powder labeled for laboratory research. The FDA treats peptides sold that way for people to use as unapproved new drugs; it said so in a June 2023 warning letter about BPC-157 and TB-500 sold as research products (FDA). Buying these vials for personal use is unsafe and unregulated: no prescriber decides whether it suits you, no licensed pharmacy answers for what is in the vial, and no one has checked its identity, strength or sterility. Our guide on whether peptides are safe explains what to check.

If a website offers you a “prescription” for compounded KPV today, treat that as a warning sign. For gut, skin or wound problems, a clinician can offer FDA-approved treatments with human evidence behind them.

The bottom line

KPV is a three-amino-acid fragment of alpha-MSH studied in cells and rodents, with no human trial behind any of the uses it is sold for. The FDA’s reviewers recommended against letting pharmacies compound it; an advisory committee disagreed 8 to 6 in July 2026, and the FDA hasn’t acted. Until a final rule adds KPV to the 503A bulks list, there is no lawful prescription source. Our peptide legal status guide tracks every popular peptide, and the peptides hub covers the ones a pharmacy may lawfully make. We’ll update this page when the FDA publishes a decision.